PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC

Clinical trial NCT06239220 · RECRUITING

Trial details

NCT number: NCT06239220
Sponsor: Dana-Farber Cancer Institute
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Head and Neck Cancer Head and Neck Squamous Cell Carcinoma Metastatic Head and Neck Cancer Recurrent Head and Neck Cancer Metastatic Head-and-neck Squamous-cell Carcinoma Recurrent Head and Neck Squamous Cell Carcinoma

Start date: 2024-02-16
Primary completion: 2026-12-31
Enrollment: 25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.